All In Biotech

Drug Trial Radar · NCT00269568

Mifepristone at Same Time Multicenter Study

A Multicenter, Randomized Comparison of Mifepristone and Misoprostol Administered Simultaneously Versus 24 Hours Apart for Abortion Through 63 Days

Last checked: Nov 20, 2026Latest source record: Jan 29, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 1,128 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,128

Actual

Start

Jun 2004

Primary completion

Apr 2006

Study completion Apr 2006

Sponsor

Lead sponsor
University of PittsburghAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 23, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized study. 564 healthy women, age 18 years or older, with an intrauterine pregnancy, and requesting a medical abortion, will be recruited to participate in this prospective clinical trial. This study will provide an evaluation of oral mifepristone 200 mg and vaginal misoprostol 800 mcg administered simultaneously in women up to 63 days gestation. The aims of the study are to compare the complete abortion rates, at 7 and 14 days after misoprostol administration, when using mifepristone 200 mg orally and misoprostol 800 mcg vaginally are administered simultaneously and 24 hours apart in women up to 63 days gestation. Assessment of side effects (nausea, vomiting, pain) as well as acceptability will be done using pre and post-study questionnaires, and visual analogue scales. Complete abortion rate within 24 hours is expected to be 90%

Conditions

  • Abortion Seekers

Interventions

  • mifepristone and misoprostolDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. complete abortion rateTime frame: 5 weeks after treatment

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • University of Southern California

    Los Angeles, California

  • Northwestern University

    Chicago, Illinois

  • Oregon Health Sciences University

    Portland, Oregon

  • Magee-Womens Hospital

    Pittsburgh, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.